A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors
Anyue Yin,Dirk Jan A.R. Moes,Johan G.C. van Hasselt,Jesse J. Swen,Henk-Jan Guchelaar +4 more
- Vol. 8, Iss: 10, pp 720-737
TLDR
The opportunities of a model‐based approach as discussed in this review can be of great benefit for future optimizing and personalizing anticancer treatment.Abstract:
Increasing knowledge of intertumor heterogeneity, intratumor heterogeneity, and cancer evolution has improved the understanding of anticancer treatment resistance. A better characterization of cancer evolution and subsequent use of this knowledge for personalized treatment would increase the chance to overcome cancer treatment resistance. Model-based approaches may help achieve this goal. In this review, we comprehensively summarized mathematical models of tumor dynamics for solid tumors and of drug resistance evolution. Models displayed by ordinary differential equations, algebraic equations, and partial differential equations for characterizing tumor burden dynamics are introduced and discussed. As for tumor resistance evolution, stochastic and deterministic models are introduced and discussed. The results may facilitate a novel model-based analysis on anticancer treatment response and the occurrence of resistance, which incorporates both tumor dynamics and resistance evolution. The opportunities of a model-based approach as discussed in this review can be of great benefit for future optimizing and personalizing anticancer treatment.read more
Citations
More filters
Journal ArticleDOI
Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation
Deepti Mathur,B. Taylor,Walid K. Chatila,Howard I. Scher,Nikolaus Schultz,Pedram Razavi,Joao B. Xavier +6 more
TL;DR: Results support that pulsed treatments optimized by mathematical models could delay therapeutic resistance in breast cancer patients treated at MSK.
Posted Content
Quantitative in vivo imaging to enable tumor forecasting and treatment optimization.
Guillermo Lorenzo,David A. Hormuth,Angela M. Jarrett,Ernesto A. B. F. Lima,Shashank Subramanian,George Biros,J. Tinsley Oden,Thomas J. R. Hughes,Thomas E. Yankeelov +8 more
TL;DR: In this article, the main data types available from both common and emerging in vivo medical imaging technologies, and how these data can be used to obtain patient-specific parameters for common mathematical models of cancer.
Journal ArticleDOI
Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation
TL;DR: In this article , the authors investigate treatment strategies that may delay relapse using mathematical modeling and find that for a single-drug therapy, pulse treatment (short, elevated doses followed by a complete break from treatment)delays relapse compared with continuous treatment with the same total dose over a length of time.
Journal ArticleDOI
Integrating a dynamic central metabolism model of cancer cells with a hybrid 3D multiscale model for vascular hepatocellular carcinoma growth
TL;DR: In this article , a multiscale model of vascular tumour growth is proposed to model the metabolic processes occurring in individual cancer cells and the relationship between dosage, timing, and scheduling of anti-neoplastic agents and the physiological effects of tumour metabolism.
Journal ArticleDOI
Model-informed experimental design recommendations for distinguishing intrinsic and acquired targeted therapeutic resistance in head and neck cancer
Santiago D. Cárdenas,Constance J. Reznik,Ruchira Ranaweera,Feifei Song,Christine H. Chung,Elana J. Fertig,Jana L. Gevertz +6 more
TL;DR: In this article , the authors proposed a family of mathematical models, with each member of the family assuming a different timing and mechanism of resistance, and presented a method for fitting these models to individual volumetric data, and utilize model selection and parameter sensitivity analyses to ask: which member(s) of this family of models best describes HNSCC response to cetuximab, and what does that tell us about the timing and mechanisms driving resistance?
References
More filters
BookDOI
The Case Study
TL;DR: On May 25, 1977, IEEE member, Virginia Edgerton, a senior information scientist employed by the City of New York, telephoned the chairman of CSIT's Working Group on Ethics and Employment Practices, having been referred to the committee by IEEE Headquarters.
Journal ArticleDOI
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan,Charles E. Massie,Javier Garcia-Corbacho,Florent Mouliere,James D. Brenton,Carlos Caldas,Simon Pacey,Richard D. Baird,Nitzan Rosenfeld +8 more
TL;DR: The field is now in an exciting transitional period in which ctDNA analysis is beginning to be applied clinically, although there is still much to learn about the biology of cell-free DNA.
Journal ArticleDOI
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Diaz,Luis A. Diaz,Richard Thomas Williams,Jian Wu,Jian Wu,Isaac Kinde,J. Randolph Hecht,Jordan Berlin,Benjamin L. Allen,Ivana Bozic,Johannes G. Reiter,Johannes G. Reiter,Martin A. Nowak,Kenneth W. Kinzler,Kelly S. Oliner,Bert Vogelstein +15 more
TL;DR: Results suggest that the emergence of KRAS mutations is a mediator of acquired resistance to EGFR blockade and that these mutations can be detected in a non-invasive manner, which explains why solid tumours develop resistance to targeted therapies in a highly reproducible fashion.
Journal ArticleDOI
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing
Charissa Kim,Ruli Gao,Emi Sei,Rachel Brandt,Johan Hartman,Thomas Hatschek,Nicola Crosetto,Theodoros Foukakis,Nicholas Navin +8 more
TL;DR: The data showed that resistant genotypes were pre-existing and adaptively selected by NAC, while transcriptional profiles were acquired by reprogramming in response to chemotherapy in TNBC patients.
Book ChapterDOI
The Mathematical Model
TL;DR: The death rate per tumor cell due to immunological response is proportional to the total number of antigen-producing (tumor) cells; thus, the total death rate is quadratic.